Challenges of Pancreatic Cancer. Review uri icon

Overview

abstract

  • The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.

publication date

  • January 1, 2015

Research

keywords

  • Epithelial Cells
  • Molecular Imaging
  • Pancreatic Neoplasms
  • Positron-Emission Tomography

Identity

PubMed Central ID

  • PMC4517183

Scopus Document Identifier

  • 84930589944

Digital Object Identifier (DOI)

  • 10.1097/PPO.0000000000000109

PubMed ID

  • 26049698

Additional Document Info

volume

  • 21

issue

  • 3